PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.45 AUD Market Closed
Market Cap: 676.6m AUD
Have any thoughts about
PYC Therapeutics Ltd?
Write Note

PYC Therapeutics Ltd
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

PYC Therapeutics Ltd
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
PYC Therapeutics Ltd
ASX:PYC
Cash from Operating Activities
-AU$38.6m
CAGR 3-Years
-48%
CAGR 5-Years
-50%
CAGR 10-Years
-28%
Immutep Ltd
ASX:IMM
Cash from Operating Activities
-AU$35.4m
CAGR 3-Years
-26%
CAGR 5-Years
-18%
CAGR 10-Years
-10%
Mesoblast Ltd
ASX:MSB
Cash from Operating Activities
-$48.5m
CAGR 3-Years
22%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cash from Operating Activities
$2.8B
CAGR 3-Years
-9%
CAGR 5-Years
11%
CAGR 10-Years
7%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cash from Operating Activities
AU$37.1m
CAGR 3-Years
24%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cash from Operating Activities
AU$23.9m
CAGR 3-Years
130%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PYC Therapeutics Ltd
Glance View

Market Cap
684.7m AUD
Industry
Biotechnology

PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.

PYC Intrinsic Value
1.1 AUD
Overvaluation 24%
Intrinsic Value
Price

See Also

What is PYC Therapeutics Ltd's Cash from Operating Activities?
Cash from Operating Activities
-38.6m AUD

Based on the financial report for Jun 30, 2024, PYC Therapeutics Ltd's Cash from Operating Activities amounts to -38.6m AUD.

What is PYC Therapeutics Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-28%

Over the last year, the Cash from Operating Activities growth was -58%. The average annual Cash from Operating Activities growth rates for PYC Therapeutics Ltd have been -48% over the past three years , -50% over the past five years , and -28% over the past ten years .

Back to Top